Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway

Katsuyoshi Tsukii, Executive Officer, Senior Vice President, Head of Development Division, Head of Development Management Office, Kyowa Kirin Kyowa Kirin is doubling down on the development of tivozanib eye drops (KHK4951) to offer a less invasive treatment option for patients...read more